- Behavioral Medicine & Psychiatry
- Clinical Faculty
- Department of Neuroscience
- Rockefeller Neuroscience Institute (SOM)
- MSW, Columbia University, 1994
Herczyk JM, Zullig KJ, Davis SM, Mallow J, Hobbs GR, Davidov DM, Lander LR, Theeke L. Association of Loneliness and Mindfulness in Substance Use Treatment Retention. Int J Environ Res Public Health 2023;20(16):6571. PMID: 37623157. PMCID: PMC10454177. DOI: 10.3390/ijerph20166571
Rezai AR, Mahoney JJ, Ranjan M, Haut MW, Zheng W, Lander LR, Berry JH, Farmer DL, Marton JL, Tirumalai P, Mears A, Thompson-Lake DGY, Finomore VS, D'Haese PF, Aklin WM, George DT, Corrigan JD, Hodder SL. Safety and feasibility clinical trial of nucleus accumbens deep brain stimulation for treatment-refractory opioid use disorder. Journal of Neurosurgery 2023:1-9. Epub ahead of print. PMID: 37329519. DOI: 10.3171/2023.4.JNS23114
Cox J, Reid N, Lander L. Long-term effects of medication for opioid use disorder in children. JAAPA 2022;35(4):1-4. PMID: 35348547. DOI: 10.1097/01.JAA.0000823148.49509.67
Mills R, Zullig KJ, Theeke LA, Lander LR, Hobbs GR, Herczyk J, Davis SM. Assessing Loneliness among Adults Receiving Outpatient Treatment with Medication for Opioid Use Disorder (MOUD). Int J Environ Res Public Health 2022;19(20):13481. PMID: 36294057. PMCID: PMC9602554. DOI: 10.3390/ijerph192013481
Stoltman JJK, Lander LR, Patrick JH, Terplan M, Jones HE. Interest in Co-located Reproductive and Sexual Health Services Among Women and Men Receiving Medication for Opioid Use Disorder in an Outpatient Treatment Clinic. Front Psychiatry 2022;13:910389. PMID: 35873229. PMCID: PMC9299362. DOI: 10.3389/fpsyt.2022.910389
Wang K, DiChiacchio T, Fang W, Lander L, Feinberg J, Xie C, Winstanley EL, Ubolrat Piamjariyakul. Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale. J Affect Disord 2022;297:148-155. PMID: 34670131. DOI: 10.1016/j.jad.2021.10.018
Winstanley EL, Thacker EP, Choo LY, Lander LR, Berry JH, Tofighi B. Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use. Drug and Alcohol Dependence Reports 2022;5:100091. DOI: 10.1016/j.dadr.2022.100091
Mahoney JJ, Haut MW, Hodder SL, Zheng W, Lander LR, Berry JH, Farmer DL, Marton JL, Ranjan M, Brandmeir NJ, Finomore VS, Hensley JL, Aklin WM, Wang GJ, Tomasi D, Shokri-Kojori E, Rezai AR. Deep brain stimulation of the nucleus accumbens/ventral capsule for severe and intractable opioid and benzodiazepine use disorder. Experimental and Clinical Psychopharmacology 2021;29(2):210-5. PMID: 34043402. DOI: 10.1037/pha0000453
Mahoney JJ, Winstanley EL, Lander LR, Berry JH, Marshalek PJ, Haut MW, Marton JL, Kimble WD, Armistead, Wen S, Cai Y, Hodder SL. High prevalence of co-occurring substance use in individuals with opioid use disorder. Addictive Behaviors 2021;114:106752. PMID: 33348147. DOI: 10.1016/j.addbeh.2020.106752
Winstanley EL, Lander LR, Zheng W, Law KB, Six-Workman A, Berry JH. Rapid Transition of Individual and Group-based Behavioral Outpatient Visits to Telepsychiatry in Response to COVID-19. Journal of Addiction Medicine 2021;15(3):263-265. PMID: 33105168. DOI:10.1097/ADM.0000000000000748
Zullig KJ, Lander LR, Tuscano M, Garland M, Hobbs GR, Faulkenberry L. Testing Mindfulness-Based Relapse Prevention with Medications for Opioid Use Disorder Among Adults in Outpatient Therapy: a Quasi-experimental Study. Mindfulness (N Y) 2021;12(12):3036-3046. PMID: 34659584. PMCID: PMC8504564. DOI: 10.1007/s12671-021-01763-w
Winstanley EL, Mahoney JJ, Lander LR, Berry JH, Marshalek P, Zheng W, Haut MW. (2020). Something to Despair: Gender differences in adverse childhood experiences among rural patients. Journal of Substance Abuse Treatment, 116; 1-7. Dx.doi.org/10.1016/j.jsat.2020.108056
Lander LR, Zheng W, Hustead J, Mahoney JJ, Berry JH, Marshalek P, Winstanley EL. (2020). Long-term treatment retention in West Virginia’s Comprehensive Opioid Addictions Treatment Program. Journal of the Neurological Sciences, Vol 411, Article 116712. https://doi.org/10.1016/j.jns.2020.116712
Mahoney JJ, Marshalek PJ, Rezai AR, Lander LR, Berry, JH, Haut MW. A Case Report Illustration the Effects of Repetitive Transcranial Magnetic Stimulation on Cue-Induced Craving in an Individual with Opioid and Cocaine Use Disorder. Experimental and Clinical Psychopharmacology. October 2019. Dx.doi.org/10.1037/pha0000289
Winstanley EL, Lander LR, Berry JH, Mahoney JJ, Zhang W, Herschler J, Marshalek P, Sayres S, Mason J, Haut MW. West Virginia’s model of buprenorphine expansion: Preliminary results. Journal of Substance Abuse Treatment, May 2019. doi.org/101016/j.jsat.2019.05.005
Shane W. Kaski, BS; Stephan Brooks, MPH; Sijin Wen, PhD; Marc W. Haut, PhD;
David P. Siderovski, PhD; Laura R. Lander, MSW; Vincent Setola, PhD. Four single nucleotide polymorphisms in genes involved in neuronal signaling are associated with Opioid Use Disorder in West Virginia, Journal of Opioid Management. 2019; 15(2). DOI: http://dx.doi.org/10.5055/jom.2019.0491
Zullig, Keith J., Lander, Laura R., Tuscano, Meghan, Hobbs, Gerry R., & Faulkenberry, Laurel. (2018). Incorporating Mindfulness-Based Relapse Prevention into outpatient therapy for treatment of opioid use disorder with medication-assisted treatment. Annals of Community Medicine & Practice Volume 4, Issue 1: 1032. https://www.jscimedcentral.com/CommunityMedicine/communitymedicine-4-1032.pdf
Nguyen L, Lander LR, O'Grady KE, Marshalek PJ, Schmidt A, Kelly AK, Jones HE. Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure. Am J Addict. 2018 Mar;27(2):92-96. doi: 10.1111/ajad.12687. Epub 2018 Feb 23. https://www.ncbi.nlm.nih.gov/pubmed/29473258
Zheng, W., Nickasch, M., Lander, L., Wen, S., Xiao, M., Marshalek, P., Dix, E, Sullivan, C. (2017). Treatment Outcome Comparison between Telepsychiatry and Face-to-face Buprenorphine Medication-Assisted Treatment (MAT) for Opioid Use Disorder: A 2-Year Retrospective Data Analysis. Journal of Addiction Medicine, 11(2), 138–144. http://doi.org/10.1097/ADM.0000000000000287
Laura Lander, Kathleen Chiasson-Downs, Michael Andrew, Gerald Rader, Sheena Dohar, and Kimberly Waibogha, Yoga as an Adjunctive Intervention to Medication-Assisted Treatment with Buprenorphine+Naloxone, Journal of Addiction Research & Therapy 2017, 8:6, DOI: 10.4172/2155-6105.1000354
Keith J. Zullig ,Laura R. Lander, Samantha Sloan, Michael R. Brumage, Gerry R. Hobbs, Laurel Faulkenberry., Mindfulness-Based Relapse Prevention with Individuals Receiving Medication-Assisted Outpatient Treatment for Opioid Use Disorder, Mindfulness, April 2018, Volume 9, Issue 2, pp 423–429, https://doi.org/10.1007/s12671-017-0784-0
Zheng, Wanhong, Nickasch, Michael, Lander, Laura, Wen, Sijin, Xiao, Minchan, Marshalek, Patrick, Dix, Ebony, Sullivan, Carl. Treatment Outcome Comparison between Telepsychiatry and Face-to-face Buprenorphine Medication-assisted Treatment for Opioid Use Disorder: A 2-Year Retrospective Data Analysis. Journal of Addiction Medicine. 11(2):138-144, March/April 2017. DOI: 10.1097/ADM.0000000000000287
Zullig, K, Lander, L, Sloan, S, Brummage, M, Hobbs, G, Faulkenberry, L. Mindfulness-Based Relapse Prevention with Individuals Receiving Medication-Assisted Outpatient Treatment for Opioid Use Disorder, Mindfulness. 8/2017. DOI 10.1007/s12671-017-0784-0
Lander, L & Marshalek, P. Opioid Use Disorder Among Pregnant Women: effective substance abuse treatment considerations. Paradigm. 21(4) 2017, 20-22.
Stabler ME, Long DL, Chertok IR, Giacobbi PR Jr, Pilkerton C, Lander LR. Neonatal Abstinence Syndrome in West Virginia Substate Regions, 2007-2013. The Journal of Rural Health, 2016 Feb, doi 10.1111/jrh. 12174
Zheng WH, Wakim RJ, Geary RC, Lander LR, Wen SJ, Xiao MC and Sullivan CR. Self-reported Sleep Improvement in Buprenorphine MAT (Medication Assisted Treatment) Population. Austin Journal of Drug Abuse and Addiction - Vol.3, Issue 1 -2016; 3 (1): 1009.
Stabler M, Gurka K, Lander L. Association between Childhood Residential Mobility and Non-Medical Use of Prescription Drugs among American Youth, submitted to Maternal and Child Health Journal, Aug, 2014.
Lander L, Gurka K, Marshalek P, Riffon M, Sullivan R. Treatment of Pregnant Women With Opioid Use Disorders on Buprenorphine in Pregnancy-Only vs. Mixed-Gender Groups, submitted to SW Research, (2015) 39 (4): 235-244.
Byrne M & Lander L. (2014) Chapter 4: Socio-environmental Aspects of substance Use Disorders. In A. Douaihy & D. Daley (Eds), Substance Use Disorders (Pittsburgh Pocket Psychiatry Series). New York: Oxford University Press.
Lander L, Marshalek P, Yitayew M, Ford D, Sullivan C, Gurka K. (2013) Rural Healthcare Disparities: Challenges and Solutions for the Pregnant Opioid-dependent Population. West Virginia Medical Journal Accepted for publication July 2013.
Shockey, A, Wilson CS, Lander L, Baretto, G, Szklarz, G, VanVoorhis, G, Minardi, J. (2013). The effect of rural upbringing and education on the intent of health professional students to work in rural settings. International Journal of Medical Education Volume 4, 18-25.
White RJ, Zullig KJ, Lander L, Shockley C, Pack RP, Sullivan C. (2012). The West Virginia Prescription Drug Abuse Quitline: Challenges and Lessons Learned from Running a Remote Quitline, Health Promotion Practice Volume 13(1), 81-89.
About Laura Lander
Laura Lander, MSW, AADC is an Associate Professor Social Work Section Chief and Addiction Therapist in the Department of Behavioral Medicine & Psychiatry, and Department of Neuroscience, at West Virginia University, School of Medicine. She graduated with a Masters in Social Work from Columbia University in 1994, and currently holds licensure as an Independent Clinical Social Worker under the West Virginia Board of Social Work Licensure. Ms. Lander has over 25 years of clinical experience in the field of mental health and substance abuse and has worked to develop a nationally recognized innovative model of group-based (MAT) with buprenorphine for individuals with OUD, and an integrated MAT Centering model specifically for the treatment of pregnant women. Ms. Lander’s primary research focus is clinical translational research in the area of opioid use disorders (OUD) and developing effective ways to measure and improve clinical outcomes. Ms. Lander is a Co-Investigator in the NIDA Clinical Trials Network Appalachian Node. Her research over the last 15 years has primarily focused on developing effective therapeutic interventions for the treatment of substance use disorders among both men and women, pregnant women, and adolescents. She has incorporated the use of genetics, neuroimaging and adjunctive treatments such as yoga and mindfulness-based relapse prevention to measure and improve treatment effectiveness. The treatment of pregnant women with OUD and assessment of neonatal outcomes is also an area of clinical and research focus. She is currently Co-Investigator on several SAMHSA SOR grants including MAT expansion in WV, initiation of buprenorphine in the ED using Peer Recovery Support Specialists and is a member of the Addictions Center of Excellence at WVU. Through her research efforts she strives to develop ways to develop evidence-based treatments for patients struggling with substance use disorders.
Ms. Lander’s primary research focus is clinical translational research in the area of opioid use disorders (OUD) and developing effective ways to measure and improve clinical outcomes. She is currently an Associate Professor in the West Virginia University (WVU) School of Medicine, with a dual appointment in the Department of Behavioral Medicine and Psychiatry and Department of Neuroscience. Ms. Lander is recognized as a national expert on medication-assisted treatment (MAT) for OUD and served on the National Academies of Sciences, Engineering and Medicine Committee on MAT for OUD from 10/2018-3/2019. She is a Co-Investigator in the National Institute on Drug Abuse Clinical Trials Network in the newly formed Appalachian Node. Her additional research in the last 15 years has primarily focused on developing effective psychosocial interventions for the treatment of substance use disorders among both men and women, pregnant women, and adolescents. She has incorporated the use of genetics, neuroimaging and adjunctive treatments such as yoga and mindfulness-based relapse prevention to measure and improve treatment effectiveness. The treatment of pregnant women with OUD and assessment of neonatal outcomes is also an area of clinical and research focus. She is currently Co-Investigator on several SAMHSA State Opioid Response grants including MAT expansion in WV, initiation of buprenorphine in the ED using Peer Recovery Coach Support and is a member of the Addictions Center of Excellence at WVU. In addition, she has over 25 years of clinical experience in the field of mental health and substance abuse and has worked to develop a nationally recognized innovative model of group-based MAT with buprenorphine for individuals with OUD, and an integrated MAT Centering model specifically for the treatment of pregnant and post-partum women. From this clinical experience, she has developed a deep understanding of the challenges faced by patients with substance use disorders and their families and the barriers to treatment. Through her research efforts, she strives to develop ways to develop evidence-based treatments for patients struggling with substance use disorders.
Patient Care Information
- Behavioral Medicine and Psychiatry
Other Speciality Training, Dialectical Behavioral Therapy
McLean Hospital, 2004
Other Speciality Training, Family Therapy
Westchester Family Institute, 1997
Working with families impacted by Addiction